ProShare Advisors LLC Grows Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

ProShare Advisors LLC lifted its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 44.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,925 shares of the company's stock after buying an additional 4,590 shares during the quarter. ProShare Advisors LLC's holdings in Prestige Consumer Healthcare were worth $1,165,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of PBH. Kayne Anderson Rudnick Investment Management LLC purchased a new stake in Prestige Consumer Healthcare during the fourth quarter worth about $84,932,000. Raymond James Financial Inc. acquired a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $42,593,000. Norges Bank purchased a new stake in Prestige Consumer Healthcare during the 4th quarter worth approximately $40,009,000. Bessemer Group Inc. increased its stake in Prestige Consumer Healthcare by 10,053.1% during the 4th quarter. Bessemer Group Inc. now owns 295,050 shares of the company's stock worth $23,041,000 after buying an additional 292,144 shares during the period. Finally, Boston Trust Walden Corp lifted its holdings in Prestige Consumer Healthcare by 43.5% during the 4th quarter. Boston Trust Walden Corp now owns 831,627 shares of the company's stock worth $64,942,000 after buying an additional 252,089 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Up 0.6%

Shares of NYSE PBH opened at $84.89 on Friday. The business has a 50-day moving average of $83.48 and a two-hundred day moving average of $82.17. The company has a market capitalization of $4.19 billion, a price-to-earnings ratio of 19.88, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44. Prestige Consumer Healthcare Inc. has a 1 year low of $62.35 and a 1 year high of $90.04. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.02. The business had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The business's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the company earned $1.02 EPS. On average, analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the sale, the senior vice president now directly owns 17,157 shares in the company, valued at $1,544,130. This trade represents a 8.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.60% of the company's stock.

Wall Street Analysts Forecast Growth

PBH has been the subject of several research reports. Wall Street Zen upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 17th. Royal Bank of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. DA Davidson increased their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Oppenheimer lifted their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research note on Thursday, February 13th. Finally, Canaccord Genuity Group upped their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.